New Danish branch expands Landmark's European footprint and enables faster, compliant RWE and HEOR for biopharma and medtech

AARHUS, Denmark — April 27, 2026 — Landmark Science, Inc. today announced the opening of its new Danish subsidiary, Landmark Science ApS, underscoring the company’s commitment to delivering high quality real world evidence (RWE) and health economics and outcomes research (HEOR) across Europe. Establishing a dedicated presence in Denmark positions Landmark Science to partner closely with European life sciences organizations, health systems, and data partners to generate robust, decision grade evidence for regulatory, market access, and clinical adoption needs.

“Across Europe, payers, regulators, and clinicians are increasingly relying on high quality real-world data to evaluate how therapies perform in diverse patient populations,” said Shivani Aggarwal, CEO of Landmark Science. “With Landmark Science ApS, we are deepening our roots in Europe to help meet our clients needs—from RWE strategy and study design to HEOR models, value dossiers, and submissions—while upholding the highest standards of scientific rigor, privacy, and compliance.”

Expanding capabilities for EU partners

From its base in Denmark, Landmark Science ApS will deliver end-to-end support for:

  • RWE strategy & target trial emulation for effectiveness and post-authorization safety, label expansions, and lifecycle evidence.
  • HEOR & market access including cost effectiveness models, budget impact analyses, and payer ready value communication.
  • Pan-EU data partnerships and study operations with stringent GDPR data governance and quality management.
  • Evidence packages to support regulatory interactions, joint clinical assessments, and health technology assessment (HTA) submissions across EU markets.

Why Denmark

Denmark’s strong digital health ecosystem, research friendly environment, and strategic location within the Nordics and EU make it an ideal hub for multi-country evidence generation. Landmark Science ApS will foster strategic partnerships with data providers, research networks, and other collaborators to advance pragmatic, patient-centered studies that demonstrate clinical and economic value.

About Landmark Science

Landmark Science is a premier life science research organization focused on real-world evidence and health economics and outcomes research. Landmark Science partners with biopharma, medtech, and digital health innovators to design and execute rigorous studies, generate regulatory grade evidence, and translate evidence into action for regulators, HTA bodies, clinicians, and payers. The company provides a comprehensive suite of services enabling the use of RWE in drug development. Our teams bring deep expertise across epidemiology, biostatistics, and data science, working globally to accelerate better outcomes for patients.

About Landmark Science ApS

Landmark Science ApS is a wholly owned Danish subsidiary of Landmark Science, established to serve clients across the EU with localized operations, data partnerships, and compliance capabilities. The company provides EU‑ready RWE and HEOR services, from study design and data acquisition to analysis, modeling, and evidence communication.

Media Contact
Landmark Science Media Relations
Email: media@landmarkscience.com
Address: Skolevej 3, 8240 Aarhus, Denmark

Business Inquiries
Email: info@landmarkscience.com